Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Aug 26, 2023 2:04pm
164 Views
Post# 35606807

RE:Slo Walking TH1902 Trial?

RE:Slo Walking TH1902 Trial?

I believe previously I was referring to initial start and the time line for it as many thought it was going to slow or it was delayed but as per my take based on the initial design it would take as long as it did until the stop! The restart has a part 3, 6+6+4 patients and part 4 total 20 patients including among others if available patients from parts 1, 2 and 3. When would they be able to announce the results would be based on the enrolment progress and of course the results. I would hope that if the results are positive they would share it as soon as they can. Point is the valuation now has issues because the costs associated with the oncology trial is priced in it, so does weak balance sheet, potential Marathon issues and weaker than anticipated sales so far. If and when there is any progress in oncology, potential renegotiation with Marathon which is not short termed and better sales etc. any of those could and should improve the market's perception of company's value. Ideally as many have suggested they should cut the costs ASAP and in my opinion that process should include less populated  board of directors and wage cuts of management including the CEO's hefty salary which the company specifically now can't afford. I guess what I am trying to say is the valuation is trashed not only because of the pessimism about the oncology but also the financial health of the company.
 




Lee430 wrote: Scarlet,
Previously you mentioned that you thought the TH1902 trial was let’s say (Slo Walking) and their timelines looked too aggressive.

That assessment sure seems to be pretty accurate now as they are almost a month past the stated start date, so when would you think we could see a PR announcing patients’ dosage has started? Would the end of August be too optimistic?


 

<< Previous
Bullboard Posts
Next >>